Literature DB >> 25632185

Weichang'an and 5-fluorouracil suppresses colorectal cancer in a mouse model.

Li Tao1, Jin-Kun Yang1, Ying Gu1, Xin Zhou1, Ai-Guang Zhao1, Jian Zheng1, Ying-Jie Zhu1.   

Abstract

AIM: To examine the effect of Weichang'an (WCA) and 5-fluorouracil (5-FU) on colorectal tumor and hepatic metastasis in a mouse model.
METHODS: Quantitative determination of hesperidin, the effective component in WCA decoction, was performed using HPLC. In vitro cytotoxicity of WCA was determined by treating HCT-116 cells with WCA diluents or serum extracted from rats that received WCA by oral gavage for 1 wk and MTT assays. Forty-eight nude mice received cecum implantation with tumor blocks subcutaneously amplified from human colon cancer cell line HCT-116. Mice were randomly divided into four treatment groups: control (CON), WCA, 5-FU and combination (WCA+5-FU). Pathological examination of tumors consisted of tissue sectioning and hematoxylin and eosin staining. Tumor weight and size were measured, and the number of metastatic lesions was counted. Serum carcinoembryonic antigen (CEA) level was determined by ELISA. The expression levels of tumor genesis and metastasis-related proteins β-catenin and matrix metalloproteinase (MMP)-7 were measured by real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR), immunohistochemistry and immunoblotting. Cell fractionation was used to investigate intracellular distribution of β-catenin.
RESULTS: Parenchymal tumors were palpable in the abdomens of nude mice 2 wk post-implantation and orthotopic tumor formation rate was 100% in all groups. 5-FU treatment alone significantly decreased tumor weight compared to the CON group (1.203±0.284 g vs 1.804±0.649 g, P<0.01). WCA treatment alone reduced the rate of metastasis (50% vs 100%, P<0.05). Combination treatment of WCA+5-FU was the most effective, reducing the tumor weight (1.140±0.464 g vs 1.804±0.649 g, P<0.01) and size (1493.438±740.906 mm3 vs 2180.259±816.556 mm3, P<0.05), the rate of metastases (40% vs 100%, P<0.01), and serum CEA levels (31.263±7.421 μg/L vs 43.040±11.273 μg/L, P<0.05). Expression of β-catenin and MMP-7 was decreased in drug-treated groups compared to controls, as detected using real-time quantitative RT-PCR, immunohistochemistry and immunoblotting, respectively. Cell fractionation assays revealed that nuclear translocation of β-catenin was reduced by WCA and/or 5-FU treatments.
CONCLUSION: Combination of WCA with 5-FU significantly inhibited colon tumor growth and hepatic metastases. Decreased expression of β-catenin and MMP-7 may be important.

Entities:  

Keywords:  Chemotherapeutics 5-fluorouracil; Colorectal cancer; Hepatic metastasis; Orthotopic transplant nude mouse model; Weichang’an formula

Mesh:

Substances:

Year:  2015        PMID: 25632185      PMCID: PMC4306156          DOI: 10.3748/wjg.v21.i4.1125

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  37 in total

Review 1.  Linking colorectal cancer to Wnt signaling.

Authors:  M Bienz; H Clevers
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

2.  Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases.

Authors:  Zhao-Shi Zeng; Wei-Ping Shu; Alfred M Cohen; José G Guillem
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

Review 3.  Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.

Authors:  Peter S Yoo; Reynold I Lopez-Soler; Walter E Longo; Charles H Cha
Journal:  Clin Colorectal Cancer       Date:  2006-09       Impact factor: 4.481

4.  Antiproliferative efficacy of hesperetin (citrus flavanoid) in 1,2-dimethylhydrazine-induced colon cancer.

Authors:  Selvaraj Aranganathan; Namasivayam Nalini
Journal:  Phytother Res       Date:  2012-08-17       Impact factor: 5.878

5.  Liver resection for colorectal metastases.

Authors:  Y Fong; A M Cohen; J G Fortner; W E Enker; A D Turnbull; D G Coit; A M Marrero; M Prasad; L H Blumgart; M F Brennan
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

Review 6.  Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.

Authors:  Eric Van Cutsem; Bernard Nordlinger; Rene Adam; Claus-Henning Köhne; Carmelo Pozzo; Graeme Poston; Marc Ychou; Philippe Rougier
Journal:  Eur J Cancer       Date:  2006-08-10       Impact factor: 9.162

Review 7.  Wnt/beta-catenin signaling in cancer stemness and malignant behavior.

Authors:  Riccardo Fodde; Thomas Brabletz
Journal:  Curr Opin Cell Biol       Date:  2007-02-16       Impact factor: 8.382

8.  Survival benefit of traditional Chinese herbal medicine (a herbal formula for invigorating spleen) for patients with advanced gastric cancer.

Authors:  Yan Xu; Ai Guang Zhao; Zhao Yan Li; Gang Zhao; Yong Cai; Xiao Hong Zhu; Ni Da Cao; Jin Kun Yang; Jian Zheng; Yin Gu; Ying Ying Han; Ying Jie Zhu; Jin Zu Yang; Feng Gao; Qiang Wang
Journal:  Integr Cancer Ther       Date:  2012-07-09       Impact factor: 3.279

9.  Factors influencing the natural history of colorectal liver metastases.

Authors:  R Stangl; A Altendorf-Hofmann; R M Charnley; J Scheele
Journal:  Lancet       Date:  1994-06-04       Impact factor: 79.321

10.  Detection of recurrences during follow-up after liver surgery for colorectal metastases: both carcinoembryonic antigen (CEA) and imaging are important.

Authors:  Charlotte J Verberne; Theo Wiggers; Karin M Vermeulen; Koert P de Jong
Journal:  Ann Surg Oncol       Date:  2012-09-05       Impact factor: 5.344

View more
  6 in total

1.  Endoscopy-guided orthotopic implantation of colorectal cancer cells results in metastatic colorectal cancer in mice.

Authors:  Dominik Bettenworth; Marcus M Mücke; Katrin Schwegmann; Andreas Faust; Christopher Poremba; Michael Schäfers; Dirk Domagk; Philipp Lenz
Journal:  Clin Exp Metastasis       Date:  2016-05-04       Impact factor: 5.150

2.  Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway.

Authors:  Wen Zhang; Ruiqian Sun; Yongjun Zhang; Rong Hu; Qian Li; Weili Wu; Xinyu Cao; Jiajian Zhou; Jianfeng Pei; Ping Yuan
Journal:  FEBS Open Bio       Date:  2021-10-11       Impact factor: 2.693

3.  Reposition of the anti-inflammatory drug diacerein in an in-vivo colorectal cancer model.

Authors:  Raghda T Abdel-Latif; Walaa Wadie; Yousra Abdel-Mottaleb; Dalaal M Abdallah; Nabila N El-Maraghy; Hanan S El-Abhar
Journal:  Saudi Pharm J       Date:  2021-12-31       Impact factor: 4.330

Review 4.  Traditional Chinese Medicine and Colorectal Cancer: Implications for Drug Discovery.

Authors:  Qiang Sun; Man He; Meng Zhang; Sha Zeng; Li Chen; Hui Zhao; Han Yang; Maolun Liu; Shan Ren; Haibo Xu
Journal:  Front Pharmacol       Date:  2021-07-01       Impact factor: 5.810

Review 5.  Recent Advances in Anti-Metastatic Approaches of Herbal Medicines in 5 Major Cancers: From Traditional Medicine to Modern Drug Discovery.

Authors:  Jinkyung Park; Dahee Jeong; Meeryoung Song; Bonglee Kim
Journal:  Antioxidants (Basel)       Date:  2021-03-27

6.  The effect of intermittent hypoxia and fecal microbiota of OSAS on genes associated with colorectal cancer.

Authors:  Jia Gao; Hailong Cao; Qiang Zhang; Bangmao Wang
Journal:  Sleep Breath       Date:  2020-10-07       Impact factor: 2.816

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.